Low Dose IL2 Immunotherapy in AD

NCT05821153 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

8

Enrollment

OTHER

Sponsor class

Conditions

Alzheimer Disease

Interventions

DRUG: Aldesleukin

Sponsor

The Methodist Hospital Research Institute